Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials

出版年份 2019 全文链接

标题

作者

关键词

PCSK9, Alirocumab, lipoprotein(a), Low-density lipoprotein cholesterol, Cardiovascular risk, Cholesterol-lowering drugs

出版物

Volume -, Issue -, Pages -

出版商

Elsevier BV

发表日期

2019-06-08

DOI

10.1016/j.atherosclerosis.2019.06.896

联系作者

Discuss science. Find collaborators. Network.

Join a conversation

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started